Overview of Structural Specifications and Validation of eCTD (v3.2.2): Elucidation of the General Architecture of EU Module 1 and GCC Module 1

Abstract

A comprehensive understanding of the eCTD structural specifications ensures compliance, accelerates the product approval process, and facilitates seamless interactions between pharmaceutical companies and regulatory authorities. This article provides an overview of the eCTD submission process and the scope of eCTD challenges and Module 1 (Region-Specific Administrative and Product Information). It provides an epitomisation of the eCTD structural specifications, along with an illustration of Module 2 folder naming and structure. The article outlines the general architecture of EU Module 1 and GCC Module 1, demonstrating the envelope, directory/file structures, as well as file naming conventions and formats. Additionally, it explains the stages of eCTD validation and some of the Validator tools; it also includes three practical cases illustrating common validation errors. Furthermore, it demonstrates the transition to eCTD version 4.0 and its implementation timeline across the EMA, FDA, Health Canada, and PMDA (Japan).

Conclusion: Conducting eCTD structural specifications governs the electronic submission framework to ensure seamless regulatory compliance. Module 1 (EU, GCC) demands precise adherence to regional regulatory requirements. Vigilance in preparing the eCTD and its validation process plays a quintessential role in minimizing submission errors, achieving approval, and enabling quicker access to new products.